MedTrace Logo

Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab

NCT04359667 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-11-12

No results posted yet for this study

Summary

This is a single arm, prospective, observational, single center study to assess the role of interleukin-6 (IL-6) and soluble interleukin 6 receptor (sIL-6R) as predictors of efficacy and safety outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab. At least 30 patients will be enrolled who are diagnosed with severe COVID-19 pneumonia and meet the entry criteria.

Conditions

Interventions

DRUG

Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]

1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)

Sponsors & Collaborators

  • University Hospital for Infectious Diseases, Croatia

    lead OTHER

Principal Investigators

  • Rok Civljak, MD, PhD · University Hospital for Infectious Diseases "Dr Fran Mihaljevic"

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2021-04-16
Completion
2021-05-15

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04359667 on ClinicalTrials.gov